Read original article on BMJ.com
A tetanus-diphtheria vaccine that can be stored at room temperature has shown promising early results in a development hailed as a potential “game changer” for global health.
Maintaining the cold chain for vaccines is a significant challenge in resource poor countries, remote communities, and regions affected by conflict.
About half of vaccines are wasted worldwide each year because of temperature changes during storage and transport, the World Health Organization has estimated.
The SPVX02 vaccine—developed by the UK based biotech company Stablepharma with support from UK Research and Innovation—aims to help change that. It is a reformulated, thermostable version of an existing tetanus-diphtheria vaccine called Tetadif, which requires refrigeration.
In a phase 1 study of the new jab 60 healthy adult volunteers were randomly assigned to receive the experimental vaccine or one of two licenced tetanus-diphtheria…
*The reuse of this article is not an endorsement of Stablepharma’s product or organisation on the part of BMJ.